Encompass Health CMO awarded 10,798 EHC shares

Encompass Health Corp Chief Medical Officer Elissa Joy Charbonneau reported stock awards in the company’s common stock.

Rhea-AI Filing Summary

Encompass Health Corp Chief Medical Officer Elissa Joy Charbonneau reported stock awards in the company’s common stock. On February 18, 2026, she acquired 8,914 shares at $0.00 per share as an annual restricted stock award under the 2025 Omnibus Performance Incentive Plan. On February 19, 2026, she acquired an additional 1,884 shares of restricted stock at $0.00 per share upon satisfaction of performance criteria from a performance share unit award granted on February 23, 2023. Following these grants, she directly owned a total of 22,756.061 shares of Encompass Health common stock.

Insider Trade Summary

Grant/Award: 10,798 shares

Grant/Award 2 txns

Insider Charbonneau Elissa Joy

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Encompass Health Common Stock	1,884	$0.00	$0.00
Grant/Award	Encompass Health Common Stock	8,914	$0.00	$0.00

Holdings After Transaction: Encompass Health Common Stock — 22,756.061 shares (Direct)

Footnotes (2)

1. F1. This issuance of restricted stock is the result of the satisfaction of performance criteria set out in the terms of a performance share unit award made on February 23, 2023.
2. F2. Annual award of restricted stock pursuant to the Corporation's 2025 Omnibus Performance Incentive Plan.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Encompass Health (EHC) report for Elissa Joy Charbonneau?

Encompass Health reported that Chief Medical Officer Elissa Joy Charbonneau acquired restricted stock in two grants totaling 10,798 shares. These were reported as awards at $0.00 per share rather than open-market purchases or sales, reflecting equity compensation rather than trading activity.

How many Encompass Health (EHC) shares did the Chief Medical Officer acquire in the latest Form 4?

The Chief Medical Officer acquired 8,914 restricted shares on February 18, 2026 and 1,884 restricted shares on February 19, 2026. Together, these equity awards increased her directly owned Encompass Health common stock to 22,756.061 shares after the reported transactions.

What is the source of the 1,884-share restricted stock issuance for Encompass Health (EHC)?

The 1,884-share restricted stock issuance results from meeting performance criteria tied to a performance share unit award granted on February 23, 2023. Once those performance targets were satisfied, the award converted into restricted shares, which were then reported as acquired stock.

What plan governs the 8,914-share restricted stock award at Encompass Health (EHC)?

The 8,914-share restricted stock grant is described as an annual award made under Encompass Health’s 2025 Omnibus Performance Incentive Plan. This indicates the shares were issued as part of the company’s long-term incentive compensation framework for executives, not via open-market transactions.

Were the Encompass Health (EHC) insider stock awards open-market purchases?

These transactions were not open-market purchases. Both entries use transaction code “A” for grants or awards at $0.00 per share. They reflect equity compensation awards, including a performance-based conversion and an annual restricted stock grant, rather than discretionary buying or selling.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/20/2026 - 03:47 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Charbonneau Elissa Joy

(Last) (First) (Middle)

9001 LIBERTY PARKWAY

(Street)

BIRMINGHAM AL 35242

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Encompass Health Corp [ EHC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Encompass Health Common Stock	02/18/2026		A		8,914(1)	A	$0	20,872.061	D
Encompass Health Common Stock	02/19/2026		A		1,884(2)	A	$0	22,756.061	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This issuance of restricted stock is the result of the satisfaction of performance criteria set out in the terms of a performance share unit award made on February 23, 2023.

2. Annual award of restricted stock pursuant to the Corporation's 2025 Omnibus Performance Incentive Plan.

	/s/ Patrick Darby, attorney-in-fact for Ms. Charbonneau	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.